Hikma Pharmaceuticals Plc

Hikma Pharmaceuticals (HIK)

Company name:Hikma Pharmaceuticals Plc
EPIC:HIKTrading Currency:GBX
Market Sector:FS10ISIN:GB00B0LCW083
Market Segment:SET1Share Type:DE
WWW Address:http://www.hikma.com/Description:ORD SHS 10P
Industry Sector:PHARMACEUTICALS & BIOTECHNOLOGY
 Price Price Change [%] Bid Offer Open High Low Volume
 2,199.00 images.advfn.com/imagesnew/2/gb/down -149.0 [-6.35] 2,194.00 2,198.00 2,360.00 2,394.00 2,096.00 1,339,454
 Market Cap. [m] Shares In Issue [m] Beta EPS DPS PE Ratio Yield 52-Wks-Range
 5,320.56 241.95 -0.71 164.33 33.18 13.38 1.51 2,394.00 - 1,553.00

Hikma Pharmaceuticals Key Figures

(at previous day's close)
Market Cap.5,320.56m
Shares In Issue241.95m
Prev. Close2,348.00
PE Ratio13.38 
Dividend Yield1.51%
EPS - basic164.33p
Dividend PS33.18p
Dividend Cover- 
Cash Flow PS147.10p
Return On Equity (ROE)22.96%
Operating Margin22.29%
PEG Factor0.19 
EPS Growth Rate71.62%
Dividends PS Growth Rate15.79%
Net Debt1,023.98m
Gross Gearing45.83%
Quick Assets1,148.39m
Net Working Capital467.50m
Intangibles / Fixed Assets48.07%
Turnover PS686.55p
Pre-Tax Profit PS153.02p
Retained Profit PS121.23p
Cash PS138.06p
Net Cash PS-320.37p
Net Tangible Asset Value PS *384.26p
Net Asset Value PS663.49p
Spread4.00 (0.18%) 

Hikma Pharmaceuticals Balance Sheet

LSE:HIK:Liabilities+EQLSE:HIK:Assets

Share Price Performance

Sample Period HighLow
1 week2,394.001,937.50
4 weeks2,394.001,596.00
12 weeks2,394.001,596.00
1 year2,394.001,553.00

Share Price Chart (5 years)

Hikma Pharmaceuticals Historic Returns

Period OpenChange%Open Avg.Avg. Daily Vol [m]Total Vol [m]VWAP
1 week1,937.50261.5013.501,937.500.952,191.36
4 weeks1,865.50333.5017.881,596.000.901,911.42
12 weeks1,909.50289.5015.161,596.000.561,900.25
26 weeks2,057.00142.006.901,596.000.481,927.10
1 year1,792.50406.5022.681,553.000.601,874.81
3 years1,879.00320.0017.03814.200.701,554.91
5 years2,190.009.000.41814.200.651,738.15

Hikma Pharmaceuticals Key Management Ratios

Hikma Pharmaceuticals Investment Ratios

(Market value analysis) at previous day's close
PQ Ratio14.29 
PE Ratio13.38 
Tobin's Q Ratio 1.43 
Tobin's Q Ratio (excl. intangibles)1.84 
Dividend Yield1.51%
Market-to-Book Ratio3.33 
Price-to-Pre-Tax Profit PS14.37 
Price-to-Retained Profit PS18.14 
Price-to-Cash Flow PS14.95 
Price-to-Sales PS3.20 
Price-to-Net Tangible Asset Value PS5.67 
Price-to-Cash PS15.93 
Net Working Capital PS193.22 
Price Pct to Working Capital PS11.38%
Earnings Yield7.47%
Average PE17.69 
Years in average4 
PE to PE average75.63%

Hikma Pharmaceuticals Financial Ratios

(Leverage Ratios)
Debt Ratio13.42%
Debt-to-Equity Ratio0.16 
Debt-to-Equity Ratio (excl. Intgbl)0.27 
Debt-to-Equity Market Value0.05 
Net Gearing34.55%
Net Gearing (excl. Intangibles)44.58%
Gross Gearing45.83%
Gross Gearing (excl. Intangibles)59.13%
Gearing Under 1 Year37.43%
Gearing Under 1 Year (excl. Intgbl)48.29%
Assets/Equity1.85 
Cash/Equity20.81 
(Liquidity Ratios)
Net Working Capital to Total Assets15.78%
Current Ratio1.42 
Quick Ratio (Acid Test)1.04 
Liquidity Ratio0.30 
Cash & Equiv/Current Assets21.19%
(Solvency Ratios)
Enterprise Value5,244.41m
CFO/Sales0.21 
CFO/Attributable Profit0.97 
CFO/Assets0.12 
CFO/Debt0.26 
Total Debt/Equity Market Value0.26 
Total Debt/Sales0.82 
Total Debt/Pre-Tax Profit3.67 
Total Debt1,358.02m
Total Debt/Net Current Assets2.90%
(Dodds - Graham Ratios)
3 yr Compound Earnings Growth-%
5 yr Compound Earnings Growth9.66%
10 yr Compound Earnings Growth14.60%
Earn drops > 5% in 10yrs5 
Beta (60-Mnth)Beta (36-Mnth)
-0.7071-0.3360

Hikma Pharmaceuticals Operating Ratios

(Profitability Ratios)
Return On Capital Employed (ROCE)19.97%
Return On Assets (ROA)9.87%
Net Profit Margin22.06%
Assets Turnover0.45 
Return On Equity (ROE)22.96%
Return On Investment (ROI)14.48%
Dividend Payout Ratio21.91%
Plowback Ratio78.09%
Growth from Plowback Ratio15.05%
Net Income Of Revenues17.66%
(Asset Utilisation Multiples)
Shareholders Equity Turnover0.87 
Fixed Assets Turnover0.94 
Current Assets Turnover0.86 
Net Working Capital Turnover 
Inventory Turnover3.03 
(Other Operating Ratios)
Total Assets-to-Sales2.24 
Debtors-to-Sales59.33%
Debt Collection Period216.54Days

Hikma Pharmaceuticals Dividends

Announcement DateTypeCurr.Dividend AmountPeriod StartPeriod EndEx DateRecord DatePayment DateTotal Dividend Amount
27 Feb 2020FinalUSX30.0031/12/201831/12/201919/03/202020/03/202007/05/202044.00
09 Aug 2019InterimUSX14.0031/12/201831/12/201922/08/201923/08/201923/09/2019-
13 Mar 2019FinalUSX26.0031/12/201731/12/201804/04/201905/04/201922/05/201938.00
15 Aug 2018InterimUSX12.0031/12/201731/12/201823/08/201824/08/201821/09/2018-
14 Mar 2018FinalUSX23.0031/12/201631/12/201705/04/201806/04/201824/05/201834.00
17 Aug 2017InterimUSX11.0031/12/201631/12/201724/08/201725/08/201722/09/2017-
15 Mar 2017FinalUSX22.0031/12/201531/12/201606/04/201707/04/201725/05/201733.00
26 Aug 2016InterimUSX11.0031/12/201531/12/201601/09/201602/09/201630/09/2016-
16 Mar 2016FinalUSX21.0031/12/201431/12/201507/04/201608/04/201619/05/201632.00
19 Aug 2015InterimUSX11.0031/12/201431/12/201527/08/201528/08/201525/09/2015-
11 Mar 2015FinalUSX9.9031/12/201331/12/201416/04/201517/04/201521/05/201516.90
11 Mar 2015SpecialUSX4.0031/12/201331/12/201416/04/201517/04/201521/05/2015-
20 Aug 2014SpecialUSX4.0031/12/201331/12/201427/08/201429/08/201426/10/2014-
20 Aug 2014InterimUSX7.0031/12/201331/12/201427/08/201429/08/201426/10/2014-
12 Mar 2014SpecialUSX2.4031/12/201231/12/201323/04/201425/04/201422/05/2014-
12 Mar 2014FinalUSX7.8031/12/201231/12/201323/04/201425/04/201422/05/201412.30
21 Aug 2013InterimUSX4.5031/12/201231/12/201304/09/201306/09/201307/10/2013-
21 Aug 2013SpecialUSX1.9031/12/201231/12/201304/09/201306/09/201307/10/2013-
13 Mar 2013FinalUSX10.0031/12/201131/12/201217/04/201319/04/201323/05/201316.00
16 Aug 2012InterimUSX6.0031/12/201131/12/201229/08/201231/08/201208/10/2012-
14 Mar 2012FinalUSX7.5031/12/201031/12/201118/04/201220/04/201224/05/201213.00
25 Aug 2011InterimUSX5.5031/12/201031/12/201107/09/201109/09/201113/10/2011-
16 Mar 2011FinalUSX7.5031/12/200931/12/201013/04/201115/04/201126/05/201113.00
26 Aug 2010InterimUSX5.5031/12/200931/12/201008/09/201010/09/201014/10/2010-
17 Mar 2010FinalUSX6.5031/12/200831/12/200914/04/201016/04/201027/05/201011.00
17 Mar 2009FinalUSX4.0031/12/200731/12/200829/04/200901/05/200902/06/20097.50
27 Aug 2009InterimUSX4.5030/12/200730/06/200816/09/200918/09/200916/10/2009-
28 Aug 2008InterimUSX3.5030/12/200730/06/200817/09/200819/09/200817/10/2008-
18 Mar 2008FinalUSX4.0001/07/200731/12/200730/04/200802/05/200802/06/20087.50
05 Sep 2007InterimUSX3.5030/12/200630/06/200726/09/200728/09/200726/10/2007-
20 Mar 2007FinalUSX2.1031/12/200531/12/200616/05/200718/05/200718/06/20073.70
13 Sep 2006InterimUSX1.6030/12/200530/06/200627/09/200629/09/200627/10/2006-
25 May 2006FinalUSX0.4731/12/200431/12/200526/04/200628/04/200630/05/20060.47

Hikma Pharmaceuticals Fundamentals

 31 Dec 2016 (USD)31 Dec 2017 (USD)31 Dec 2018 (USD)31 Dec 2019 (USD)
turnover1,950.00100.00%1,936.00100.00%2,070.00100.00%2,203.00100.00%m
pre tax profit210.0010.77%-738.00-38.12%293.0014.15%491.0022.29%m
attributable profit155.007.95%-843.00-43.54%282.0013.62%486.0022.06%m
retained profit78.004.00%-922.00-47.62%198.009.57%389.0017.66%m
eps - basic66.50 -351.30 117.00 200.80 
eps - diluted66.20 -349.80 116.50 200.00 
dividends per share33.00 34.00 38.00 44.00 

Hikma Pharmaceuticals Balance Sheet

 31 Dec 2016 (USD)31 Dec 2017 (USD)31 Dec 2018 (USD)31 Dec 2019 (USD)
LSE:HIK:Liabilities+EQLSE:HIK:AssetsLSE:HIK:Liabilities+EQLSE:HIK:AssetsLSE:HIK:Liabilities+EQLSE:HIK:AssetsLSE:HIK:Liabilities+EQLSE:HIK:Assets
 31 Dec 2016 (USD)31 Dec 2017 (USD)31 Dec 2018 (USD)31 Dec 2019 (USD)
ASSETS
fixed assets fixed assets969.0022.21%828.0024.44%870.0024.88%912.0023.21%m
intangibles intangibles1,719.0039.40%785.0023.17%766.0021.90%884.0022.49%m
fixed investments fixed investments55.001.26%66.001.95%68.001.94%43.001.09%m
current assets - other current assets - other66.001.51%95.002.80%59.001.69%39.000.99%m
stocks stocks459.0010.52%488.0014.40%528.0015.10%568.0014.45%m
debtors debtors933.0021.38%895.0026.42%930.0026.59%1,041.0026.49%m
cash & securities cash & securities162.003.71%231.006.82%276.007.89%443.0011.27%m
TOTAL4,363.00100%3,388.00100%3,497.00100%3,930.00100%m
LIABILITIES
creditors - short creditors - short918.0021.04%797.0023.52%893.0025.54%1,471.0037.43%m
creditors - long creditors - long1,034.0023.70%1,063.0031.38%907.0025.94%330.008.40%m
creditors - other creditors - other--%--%--%--%m
subordinated loans subordinated loans--%--%--%--%m
insurance funds insurance funds--%--%--%--%m
TOTAL1,952.0044.74%1,860.0054.90%1,800.0051.47%1,801.0045.83%m
EQUITY
ord cap, reserves ord cap, reserves2,396.0054.92%1,514.0044.69%1,685.0048.18%2,117.0053.87%m
prefs, minorities prefs, minorities15.000.34%14.000.41%12.000.34%12.000.31%m
TOTAL2,411.0055.26%1,528.0045.10%1,697.0048.53%2,129.0054.17%m
OTHER
NAV Basic- - - - 
NAV Diluted- - - - 

Hikma Pharmaceuticals Cash Flow Statement

31 Dec 2016 (USD)31 Dec 2017 (USD)31 Dec 2018 (USD)31 Dec 2019 (USD)
Operating CF293.00443.00430.00472.00m
Pre-Financing CF-402.00292.00334.00321.00m
Retained CF-383.0072.0056.00166.00m

Hikma Pharmaceuticals Brokers

NameActivityTypeMnemonicCode
Deutsche Bank AG London BranchMarket Maker(MME)Broker/DealerDEUTDEUTGB2L
Evolution Securities LimitedMarket Maker(MME)Broker/DealerEVOEVBGGB21MMT
Jefferies International LtdMarket Maker(MME)Broker/DealerJEFFJEFFGB2X
J.P. Morgan Securities LtdMarket Maker(MME)Broker/DealerJPMSJPMSGB2L
Citigrp Global Mkt UK EquitiesMarket Maker(MME)Broker/DealerCITISBUKGB21
Merrill Lynch InternationalMarket Maker(MME)Broker/DealerMLSBSNCSGB2LBIC
UBS AGMarket Maker(MME)Broker/DealerUBS.UBSWGB2LEQU
Winterflood Securities LtdMarket Maker(MME)Broker/DealerWINSWNTSGB2LBIC
ADVFN Advertorial
Your Recent History
LSE
HIK
Hikma Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20200407 20:53:50